The 90-Day Corporate Pilot
Start small. Learn. Scale. Explore Family Neurohealth through a defined, low-friction pilot cohort before considering wider enterprise-wide rollout.
Why Start with a 90-Day Pilot?
Employee benefit innovations require empirical validation before scaling across thousands of employees.
The Nexynaptics 90-Day Pilot allows leadership to measure organic employee interest, observe actual completion rates across different family pathways, and examine aggregated risk indicators in a strictly confidential environment.
Key Pilot Components
Digital baseline assessment exploring sensory, cognitive, and selected life-stage domains.
Tailored launch communications, live introductory briefings, and continuous participant support.
Eligible access across Child Development, Maternal Wellbeing, Employee Sensory-Cognitive, and Ageing Parent modules.
Mid-pilot touchpoints to monitor habit formation, re-check functional indicators, and assess recovery.
Ethical, appropriate direction to qualified medical specialists where clinical evaluation is warranted.
Direct participant experience surveys measuring subjective value, cognitive relief, and benefit satisfaction.
Executive debrief detailing workforce participation rates, high-level prevalence metrics, and recommendations for annual scaling.
Apply for a 90-Day Pilot
Tell us about your organization and target cohort size. We will schedule an exploratory briefing.
Frequently Asked Questions
Straightforward, transparent answers for CHROs, Total Rewards teams, and enterprise leadership.
Nexynaptics is a corporate preventive neurohealth organisation founded by M. Ranganathan, Audiologist & Speech-Language Pathologist, bringing more than two decades of professional experience to the intersection of auditory health, sensory function, cognition, developmental monitoring and human performance.
Corporate Preventive Neurohealth is a proactive workplace health framework focused on early identification, structured monitoring and appropriate professional referral across sensory and cognitive domains, moving beyond conventional employee wellness.
Family Neurohealth is the principle that employees do not leave their families at the office. It provides a structured preventive layer spanning four key life stages: early child development, maternal wellbeing, employee sensory-cognitive performance, and healthy ageing.
Family Neurohealth is designed for CHROs, Chief People Officers, Total Rewards leaders, Employee Experience heads, GCCs, and modern enterprise employers seeking high-impact, multigenerational benefit frameworks.
The employee pathway explores selected sensory and cognitive functions relevant to communication, participation and everyday performance, including hearing acuity, speech-in-noise perception, auditory listening load, balance and vestibular indicators, attention, and cognitive recovery.
The child pathway provides structured developmental surveillance and monitoring to help employee parents identify communication, hearing, attention and learning-related indicators early.
The healthy ageing pathway supports employees and their ageing parents through structured sensory, balance, memory, and functional monitoring, combined with caregiver guidance.
The 90-Day Pilot allows an organisation to evaluate Family Neurohealth across a calibrated cohort of 100 employees over 90 days across the four life-stage pathways, providing baseline screening, follow-up touchpoints, referral guidance, and an aggregated executive summary.
Nexynaptics is designed around a clear separation between participant-level information and organisational reporting. Individual assessment data remains confidential to the participant, while employers receive only appropriate aggregated and de-identified insights.
Nexynaptics provides structured assessment, monitoring and preventive neurohealth programs. Where clinical diagnosis or treatment is required, participants should be referred to the appropriate qualified healthcare professional.
No. The healthy-ageing pathway is designed for screening, monitoring and identification of areas that may warrant further professional evaluation. It is not a dementia diagnostic service.
No. Developmental surveillance and screening can identify areas of concern that may warrant formal assessment by appropriate qualified professionals.
The program is designed so that individual health information remains protected and is not routinely disclosed to the employer. Organisational reporting uses appropriate aggregated and de-identified information.
Yes. Nexynaptics can structure modules according to workforce demographics, organisational priorities and the desired level of engagement.
Yes. A defined 90-day pilot can be used to evaluate participation, engagement, referral utilisation and program value before wider deployment.